Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients
- 2 February 2007
- journal article
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 149 (3) , 245-253
- https://doi.org/10.1007/s00701-006-1092-y
Abstract
Background. The prognosis of glioblastoma multiforme remains poor despite recent therapeutic advances. Several clinical and therapeutic factors as well as tumour characteristics have been reported as significant to survival. A more efficient determination of the prognostic factors is required to optimize individual therapeutic management. The aim of our study was to evaluate by univariate then multivariate analysis the factors that influence prognosis and particularly survival. Methods. Data of 340 patients with newly-diagnosed GBM were retrospectively analyzed. Univariate analysis of prognosis factors of survival time was performed. Factors that seemed determinant were evaluated by Kaplan–Meier survival curves. Finally, the significant factors found in univariate analysis were tested in multivariate analysis using the COX regression method. Findings. Using multivariate analysis, the following factors were found to influence survival: radiotherapy was the predominant factor followed by radical surgery, tumour location, age and chemotherapy. Patients treated with temozolomide had a markedly better survival rate than patients treated with other chemotherapies (Log-rank test P < 0.005). The values of GBM type (de novo or secondary), as well as repeated surgery and partial surgery (vs. simple biopsy) were suggested by univariate analysis but not confirmed by the COX regression method. After radical surgery, progression-free survival was correlated to overall survival (r = 0.87, P < 10e-5). Conclusions. The influence of radiotherapy on survival was greater than the influence of age, an argument supporting the proposition of radiotherapy for patients until at least age 70. In the case of recurrence, the correlation between overall survival and progression-free survival is an important factor when considering the therapeutic options. Initial radical surgery and repeated procedures dramatically influence survival. The benefit of partial surgery remains difficult to evaluate. Partial surgery could be used to decrease intracranial pressure and to minimize residual tumours in order to enable treatment by chemotherapy and radiotherapy. The value of temozolomide treatment was confirmed.Keywords
This publication has 27 references indexed in Scilit:
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Indicators of Functional Status for Primary Malignant Brain Tumour PatientsCanadian Journal of Neurological Sciences, 2005
- A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJournal of Neurosurgery, 2001
- Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary GlioblastomasLaboratory Investigation, 2000
- The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphereSurgical Neurology, 1999
- Primary and secondary glioblastomas: From concept to clinical diagnosisNeuro-Oncology, 1999
- Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs)Journal of Neuro-Oncology, 1993
- Resection, biopsy, and survival in malignant glial neoplasmsJournal of Neurosurgery, 1993
- Grading of astrocytomas: A simple and reproducible methodCancer, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958